Barriera Therapeutics develops therapies aimed at restoring and strengthening protective biological barriers, such as skin and mucosal membranes, to prevent disease progression. Their pre‑clinical programs focus on barrier‑enhancing molecules that support tissue integrity and reduce inflammation, targeting conditions where barrier dysfunction is a key factor.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases originate from compromised skin and mucosal barriers, leading to increased infection risk, inflammation, and impaired tissue healing. Current treatments often address symptoms rather than restoring the underlying barrier integrity.
Solution
Barriera Therapeutics focuses on developing pre‑clinical therapeutic candidates that reinforce and restore the body’s protective barriers, including skin and mucosal linings. Their platform employs early‑stage research to identify molecular pathways that enhance barrier formation and resilience. By improving barrier function, the approach aims to prevent disease onset and support tissue health before advancing candidates into clinical development.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking early‑stage therapeutic candidates that address barrier dysfunction across dermatology, gastroenterology, and respiratory indications.
Features
- Targeted modulation of biological pathways that govern barrier integrity in skin and mucosal tissues
- Pre‑clinical candidate pipeline validated through in‑vitro and animal models for efficacy and safety
- Platform technology adaptable to multiple barrier‑related indications, such as dermatologic disorders and mucosal infections
- Integrated biomarker assays to quantify barrier restoration and tissue resilience during development